Viridian Therapeutics (VRDN) is back in focus after reporting phase 1 data for VRDN-008, an FcRn inhibitor that cut IgG levels by 74% at peak and remained effective through 8 weeks.
Investors have reacted quickly to the VRDN-008 update, with Viridian Therapeutics posting a 65.38% 1 month share price return and a 22.70% 7 day share price return. The 3 year total shareholder return of 102.76% points to momentum that has been building over time.
Capitalize on the momentum around Viridian Therapeutics by scanning a curated 36 healthcare AI stocks that could be setting up for their own breakout moments in advanced therapies and smart drug development.Viridian Therapeutics has just re-rated sharply, yet the shares still trade below both analyst targets and some intrinsic value estimates. Is the market now ahead of itself, or still lagging where fair value points?
Most Popular Narrative: 23% Undervalued
At a last close of $30.86, the analyst consensus Narrative on Simply Wall St places Viridian Therapeutics’ fair value around $39.87, implying meaningful upside if those long range cash flow and margin assumptions prove accurate.
The current valuation implies that the market already prices in substantial TED and pipeline revenues over time. This narrative holds that Viridian Therapeutics is undervalued and that discounted cash flow-based estimates leave further potential for the share price.
See why 2 investors see Viridian Therapeutics as 23% undervalued.
Result: Fair Value of $39.87 (UNDERVALUED)
Still, if Lumvoa uptake or elegrobart timelines fall short of analyst assumptions, or margins stay weaker for longer, the Viridian Therapeutics undervaluation story could unravel.
Find out about the key risks to this Viridian Therapeutics narrative.
Another View: Viridian Therapeutics Looks Expensive On Book Value
The DCF narrative points to Viridian Therapeutics looking undervalued, yet the P/B ratio tells a very different story. VRDN trades around 7.3x book value, compared with 1.8x for the US biotech industry and 4.4x for peers. That kind of premium raises a simple question: How much execution risk are you really comfortable paying up for?
See what the numbers say about this price, find out in our valuation breakdown See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment around Viridian Therapeutics is split between optimism on the pipeline and caution on valuation, so consider acting promptly and test the story against your own risk appetite using the full breakdown of 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Viridian Therapeutics?
You have seen how quickly sentiment can shift around Viridian Therapeutics. Do not stop here when a wider set of opportunities is only a few clicks away.
- Target resilience first by scanning companies with sturdier finances using our list of solid balance sheet and fundamentals (24 results) and compare how their balance sheets stack up against your risk comfort.
- Hunt for potential mispricings by reviewing a curated 35 high quality undervalued stocks list that combines quality fundamentals with prices that screening tools suggest may be out of sync with business strength.
- Spot earlier stage opportunities by checking a focused 10 elite penny stocks with strong financials list that filters for stronger financial profiles rather than pure speculation.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com